Aclaris Therapeutics’ ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
HC Wainwright has downgraded Aclaris Therapeutics Inc (NASDAQ:ACRS).
Earlier this month, the company released topline results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (eczema).
The trial met the primary efficacy endpoint, the percent change from baseline in the Eczema Area and Severity Index (EASI) score at week 4, with statistical significance for patients treated with ATI-1777 2% twice-daily (BID) compared to patients treated with vehicle (69.7% versus 58.7% in the pooled vehicle group, p=0.035).
While not statistically superior, ATI-1777 2% once daily (QD) showed a trend toward significance (68.3% compared to 59.5% in vehicle, p=0.086).
The analyst observes that although the trial successfully achieved its …
Full story available on Benzinga.com